SM22α inhibits cell proliferation and protects against anticancer drugs and γ-radiation in HepG2 cells: Involvement of metallothioneins

Cited 17 time in scopus
Metadata Downloads

Full metadata record

DC FieldValueLanguage
dc.contributor.authorT R Kim-
dc.contributor.authorJ H Moon-
dc.contributor.authorH M Lee-
dc.contributor.authorEun Wie Cho-
dc.contributor.authorS G Paik-
dc.contributor.authorI G Kim-
dc.date.accessioned2017-04-19T09:15:37Z-
dc.date.available2017-04-19T09:15:37Z-
dc.date.issued2009-
dc.identifier.issn0014-5793-
dc.identifier.uri10.1016/j.febslet.2009.09.040ko
dc.identifier.urihttps://oak.kribb.re.kr/handle/201005/9243-
dc.description.abstractSmooth muscle protein 22-alpha (SM22α) has been postulated to affect the structure and function of the actin filament. In this study, we report on the significant induction of SM22α by cytotoxic agents in HepG2 cells. SM22α-overexpression inhibited the activation of IGF-1Rβ/Akt and Erk, consequently suppressing cell proliferation. On the other hand, SM22α-overexpressing cells became resistant to apoptotic cell death caused by cytotoxic agents, in which metallothionein (MT) isoforms, especially MT1G, were significantly induced. MT1G-overexpression also conferred cellular resistance, and SM22α regulated the expression of MT1G at a transcriptional level. This study provides the first demonstration of SM22α-induced blockage of cell proliferation and cellular resistance to overcome the detrimental effects of damaging agents.-
dc.publisherWiley-
dc.titleSM22α inhibits cell proliferation and protects against anticancer drugs and γ-radiation in HepG2 cells: Involvement of metallothioneins-
dc.title.alternativeSM22α inhibits cell proliferation and protects against anticancer drugs and γ-radiation in HepG2 cells: Involvement of metallothioneins-
dc.typeArticle-
dc.citation.titleFEBS Letters-
dc.citation.number20-
dc.citation.endPage3362-
dc.citation.startPage3356-
dc.citation.volume583-
dc.contributor.affiliatedAuthorEun Wie Cho-
dc.contributor.alternativeName김태림-
dc.contributor.alternativeName문지혜-
dc.contributor.alternativeName이희민-
dc.contributor.alternativeName조은위-
dc.contributor.alternativeName백상기-
dc.contributor.alternativeName김인규-
dc.identifier.bibliographicCitationFEBS Letters, vol. 583, no. 20, pp. 3356-3362-
dc.identifier.doi10.1016/j.febslet.2009.09.040-
dc.subject.keywordCytotoxic drug-
dc.subject.keywordIGF-1Rβ/Akt-
dc.subject.keywordLuteolin-
dc.subject.keywordMetallothionein-
dc.subject.keywordSM22α-
dc.subject.localCytotoxic drug-
dc.subject.localIGF-1Rβ/Akt-
dc.subject.localluteolin-
dc.subject.localLuteolin-
dc.subject.localmetallothionein-
dc.subject.localMetallothionein-
dc.subject.localMetallothioneins-
dc.subject.localSM22α-
dc.description.journalClassY-
Appears in Collections:
Division of A.I. & Biomedical Research > Orphan Disease Therapeutic Target Research Center > 1. Journal Articles
Files in This Item:
  • There are no files associated with this item.


Items in OpenAccess@KRIBB are protected by copyright, with all rights reserved, unless otherwise indicated.